Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
|Articles|June 6, 2022
Daily Medication Pearl: Famvir (Famciclovir)
Author(s)Saro Arakelians, PharmD
Famvir, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for adults patients who are immunocompetent with herpes labialis (cold sores); treatment of recurrent episodes of genital herpes; and treatment of recurrent episodes, suppressive therapy of recurrent episodes and herpes zoster (shingles).
Advertisement
Medication Pearl of the Day: Famvir (Famciclovir)
Indication: Famvir, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for adults patients who are immunocompetent with herpes labialis (cold sores); treatment of recurrent episodes of genital herpes; and treatment of recurrent episodes, suppressive therapy of recurrent episodes and herpes zoster (shingles).
Insight:
- Dosing: may vary from 500 to 1500 mg a day, based on the diagnosis
- Dosage forms: Tablets are in 125, 250, and 500 mg.
- Adverse events: The most common adverse events reported in at least 1 indication by >10% of adult patients are headaches and nausea.
- Mechanism of action: Famciclovir is an orally administered prodrug of the antiviral agent penciclovir.
Source:
Advertisement
Related to this article
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
5